Self-harm, Unintentional Injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment a UK population-based electronic health records study

JAMA Psychiatry

Volumn 73, Issue 6, 2016, Pages 630-637

  Hayes, Joseph F ^a   Pitman, Alexandra ^a   Marston, Louise ^a   Walters, Kate ^a   Geddes, John R ^b   King, Michael ^a   Osborn, David P J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM; OLANZAPINE; QUETIAPINE; VALPROIC ACID; BENZODIAZEPINE DERIVATIVE; LITHIUM CARBONATE; TRANQUILIZER;

ADULT; ANXIETY; ARTICLE; AUTOMUTILATION; BIPOLAR DISORDER; COHORT ANALYSIS; DEPRESSION; FEMALE; HUMAN; INJURY; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; SUICIDE; UNINTENTIONAL INJURY; UNITED KINGDOM; CROSS-SECTIONAL STUDY; ELECTRONIC HEALTH RECORD; MIDDLE AGED; PROPENSITY SCORE; SELF-INJURIOUS BEHAVIOR; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; WOUNDS AND INJURIES;

ADULT; ANTIMANIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; LITHIUM CARBONATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPENSITY SCORE; QUETIAPINE FUMARATE; SELF-INJURIOUS BEHAVIOR; SUICIDE; TREATMENT OUTCOME; UNITED KINGDOM; VALPROIC ACID; WOUNDS AND INJURIES;

EID: 84973360977     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2016.0432     Document Type: Article

References (68)

1. Singhal A, Ross J, Seminog O, Hawton K, Goldacre MJ. Risk of self-harm and suicide in people with specific psychiatric and physical disorders: comparisons between disorders using English national record linkage. J R Soc Med. 2014;107(5): 194-204.
2. Berghöfer A. Lithium and suicide. BMJ. 2013;347: f4449.
3. Owens D, Horrocks J, House A. Fatal and non-fatal repetition of self-harm: systematic review. Br J Psychiatry. 2002;181(3):193-199.
4. Baldessarini RJ, Pompili M, Tondo L. Suicide in bipolar disorder: risks and management. CNS Spectr. 2006;11(6):465-471.
5. Hayes JF, Miles J, Walters K, King M, Osborn DP. A systematic review and meta-analysis of premature mortality in bipolar affective disorder. Acta Psychiatr Scand. 2015;131(6):417-425.
6. Severus E, Taylor MJ, Sauer C, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord. 2014;2(1):15.
7. Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and networkmeta-analysis. Lancet Psychiatry. 2014;1(5):351-359.
8. Perlis RH. Hard outcomes: clinical trials to reduce suicide. Am J Psychiatry. 2011;168(10):1009-1011.
9. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.
10. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290(11):1467-1473.
11. Smith EG, Søndergard L, Lopez AG, Andersen PK, Kessing LV. Association between consistent purchase of anticonvulsants or lithium and suicide risk: a longitudinal cohort study from Denmark, 1995-2001. J Affect Disord. 2009;117(3):162-167.
12. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: ameta-analytic review [published correction appears in Bipolar Disord. 2007;9(3):314]. Bipolar Disord. 2006;8(5, pt 2):625-639.
13. Schou M. The effect of prophylactic lithium treatment on mortality and suicidal behavior: a review for clinicians. J Affect Disord. 1998;50(2-3): 253-259.
14. Søndergard L, Lopez AG, Andersen PK, Kessing LV. Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide. Bipolar Disord. 2008;10(1):87-94.
15. Marangell LB, Dennehy EB, Wisniewski SR, et al. Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: findings from STEP-BD. J Clin Psychiatry. 2008;69(6):916-922.
16. Ahearn EP, Chen P, Hertzberg M, et al. Suicide attempts in veterans with bipolar disorder during treatment with lithium, divalproex, and atypical antipsychotics. J Affect Disord. 2013;145(1):77-82.
17. Bowden CL. Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J Clin Psychiatry. 2000;61(suppl 9):35-40.
18. US Food and Drug Administration. Suicidal behavior and ideation and antiepileptic drugs. http: //ow.ly/10iLkf. Published May 5, 2009. Accessed April 5, 2016.
19. Redden L, Pritchett Y, Robieson W, et al. Suicidality and divalproex sodium: analysis of controlled studies in multiple indications. Ann Gen Psychiatry. 2011;10(1):1.
20. Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med. 2010;363(6):542-551.
21. Leon AC, Solomon DA, Li C, et al. Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: a 30-year observational study. Am J Psychiatry. 2012;169(3):285-291.
22. Reid S. Current use of antiepileptic drugs is associated with an increased risk of suicidality in people with depression but not in people with epilepsy or bipolar disorder. Evid Based Ment Health. 2011;14(1):3.
23. Koek RJ, Yerevanian BI, Mintz J. Subtypes of antipsychotics and suicidal behavior in bipolar disorder. J Affect Disord. 2012;143(1-3):27-33.
24. Yerevanian BI, Koek RJ, Mintz J. Bipolar pharmacotherapy and suicidal behavior, part 3: impact of antipsychotics. J Affect Disord. 2007;103 (1-3):23-28.
25. Hoang U, Stewart R, GoldacreMJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. BMJ. 2011;343:d5422.
26. Matson JL, González ML, Smith KR, Terlonge C, Thorson RT, Dixon DR. Assessing side effects of pharmacotherapy treatment of bipolar disorder: a 20-year review of the literature. Res Dev Disabil. 2006;27(5):467-500.
27. Elvik R. Risk of road accident associated with the use of drugs: a systematic review and meta-analysis of evidence from epidemiological studies. Accid Anal Prev. 2013;60:254-267.
28. Khalsa HM, Salvatore P, Hennen J, Baethge C, Tohen M, Baldessarini RJ. Suicidal events and accidents in 216 first-episode bipolar I disorder patients: predictive factors. J Affect Disord. 2008; 106(1-2):179-184.
29. Kovacsics CE, Gottesman II, Gould TD. Lithium's antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol. 2009;49: 175-198.
30. Fawcett J. Treating impulsivity and anxiety in the suicidal patient.Ann N Y Acad Sci. 2001;932(1): 94-102.
31. Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: amini-review. Neuropsychobiology. 2010;62(1):43-49.
32. Tondo L, Baldessarini RJ. Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients. Epidemiol Psichiatr Soc. 2009;18(3):179-183.
33. IMS Health. Statistics. http://www.epic-uk.org /our-data/statistics.shtml. Accessed January 14, 2015.
34. Blak B, Thompson M, Bourke A. National representativeness and data quality of The Health Improvement Network (THIN) database of primary care information for epidemiological research. Paper presented at: 9th Annual Conference of the UK Federation of Primary Care Research Organisations; November 27, 2006; Liverpool, England.
35. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19(4):251-255.
36. Lis Y, Mann RD. The VAMP Research multi-purpose database in the U.K. J Clin Epidemiol. 1995;48(3):431-443.
37. Chisholm J. The Read clinical classification. BMJ. 1990;300(6732):1092.
38. Davé S, Petersen I. Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidemiol Drug Saf. 2009;18 (8):704-707.
39. Health and Social Care Information Centre. Prescriptions Dispensed in the Community, Statistics for England: 2001-2011. Leeds, England: Health and Social Care Information Centre; July 31, 2012.
40. National Collaborating Centre for Mental Health. Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents. Leicester, England: British Psychological Society; 2014. NICE Clinical Guidelines CG185.
41. Nazareth I, King M, Haines A, Rangel L, Myers S. Accuracy of diagnosis of psychosis on general practice computer system. BMJ. 1993;307(6895): 32-34.
42. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4-14.
43. Hardoon S, Hayes JF, Blackburn R, et al. Recording of severe mental illness in United Kingdom primary care, 2000-2010. PLoS One. 2013;8(12):e82365. doi:10.1371/journal.pone .0082365.
44. Horsfall L, Walters K, Petersen I. Identifying periods of acceptable computer usage in primary care research databases. Pharmacoepidemiol Drug Saf. 2013;22(1):64-69.
45. Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf. 2009;18(1):76-83.
46. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 1994;151(12)(suppl):1-36.
47. Mok YM, Chan HN, Chee KS, et al; Ministry of Health.Ministry of Health clinical practice guidelines: bipolar disorder. Singapore Med J. 2011; 52(12):914-918.
48. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1-44.
49. Hayes J, Prah P, Nazareth I, et al. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. PLoS One. 2011;6(12):e28725. doi:10 .1371/journal.pone.0028725.
50. National Collaborating Centre for Mental Health. Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents. Leicester, England: British Psychological Society; 2006. NICE Clinical Guidelines CG38.
51. Lewitzka U, Jabs B, Fülle M, et al. Does lithium reduce acute suicidal ideation and behavior? a protocol for a randomized, placebo-controlled multicenter trial of lithium plus treatment as usual (TAU) in patients with suicidal major depressive episode. BMC Psychiatry. 2015;15(1):117.
52. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry. 1999;60(suppl 2):77-84.
53. Haw C, Casey D, Holmes J, Hawton K. Suicidal intent and method of self-harm: a large-scale study of self-harm patients presenting to a general hospital. Suicide Life Threat Behav. 2015;45(6):732-746.
54. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79(387): 516-524
55. Holmes WM. Using Propensity Scores in Quasi-Experimental Designs. Thousand Oaks, CA: SAGE Publications; 2013.
56. Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci. 2010;25(1):1-21.
57. Seeger JD, Kurth T, Walker AM. Use of propensity score technique to account for exposure-related covariates: an example and lesson. Med Care. 2007;45(10)(suppl 2):S143-S148.
58. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239-241.
59. D'Agostino RB Jr. Propensity scoremethods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17 (19):2265-2281.
60. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39(1):33-38.
61. StataCorp LP. Stata Statistical Software [computer program]. Release 14. College Station, TX: StataCorp LP; 2015.
62. Gibbons RD, Hur K, Brown CH, Mann JJ. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry. 2009;66(12):1354-1360.
63. Sajatovic M, Valenstein M, Blow F, Ganoczy D, Ignacio R. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatr Serv. 2007;58(6):855-863.
64. Austin PC, Mamdani MM, Stukel TA, Anderson GM, Tu JV. The use of the propensity score for estimating treatment effects: administrative versus clinical data. Stat Med. 2005;24(10):1563-1578.
65. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variablemethods. JAMA. 2007;297(3):278-285.
66. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303.
67. Psaty BM, Koepsell TD, Lin D, et al. Assessment and control for confounding by indication in observational studies. J AmGeriatr Soc. 1999;47(6): 749-754.
68. Geddes JR, Goodwin GM, Rendell J, et al; BALANCE Investigators and Collaborators. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375(9712):385-395.